Cognition Therapeutics Inc (CGTX) concluded trading on Thursday at a closing price of $0.86, with 4.95 million shares of worth about $4.26 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 12.00% during that period and on July 24, 2025 the price saw a gain of about 7.04%. Currently the company’s common shares owned by public are about 61.97M shares, out of which, 50.00M shares are available for trading.
Stock saw a price change of 26.71% in past 5 days and over the past one month there was a price change of 187.20%. Year-to-date (YTD), CGTX shares are showing a performance of -54.17% which increased to 22.86% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.22 but also hit the highest price of $2.54 during that period. The average intraday trading volume for Cognition Therapeutics Inc shares is 7.14 million. The stock is currently trading 53.60% above its 20-day simple moving average (SMA20), while that difference is up 113.71% for SMA50 and it goes to 78.03% higher than SMA200.
Cognition Therapeutics Inc (NASDAQ: CGTX) currently have 61.97M outstanding shares and institutions hold larger chunk of about 9.17% of that.
The stock has a current market capitalization of $53.42M and its 3Y-monthly beta is at 1.14. It has posted earnings per share of -$0.73 in the same period. It has Quick Ratio of 2.09 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CGTX, volatility over the week remained 9.45% while standing at 15.83% over the month.
Stock’s fiscal year EPS is expected to rise by 52.62% while it is estimated to increase by 31.29% in next year. EPS is likely to grow at an annualized rate of 32.88% for next 5-years, compared to annual growth of -16.44% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by B. Riley Securities on December 19, 2024 offering a Buy rating for the stock and assigned a target price range of between $1 and $1.50 to it. On November 03, 2021, Oppenheimer Initiated their recommendations, while on November 03, 2021, B. Riley Securities Initiated their ratings for the stock with a price target of $27.
